HF 2026: Cardio-Oncology as One of the Highlights of the European Heart Failure Congress

Dr. Pedro Barros

Dr. Pedro Barros

5 min read

May 15, 2026

Carregando conteúdo…
CardioOncology

Highlights

CardiologySnackableHealth®
December 24, 2025
7 min read

SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey

In today’s SnackableHealth® episode, Dr. Mike Gibson speaks with Dr. Tony Urey about the idea that amyloidosis can be a multisystem disease—while clinical attention has often centered on cardiac manifestations, particularly in “wild-type transthyretin amyloidosis,” which has historically been framed primarily as a cardiac condition. Dr. Urey explains that, in reviewing the HELIOS B data, the goal was to better characterize under-recognized symptoms that may affect patients’ quality of life. H

ASCOGU 2026
January 16, 2026
0 min read

ASCO GU® 2026

ASCO GU 2026 (American Society of Clinical Oncology Genitourinary Cancers Symposium) is one of the leading international events dedicated to genitourinary cancers, bringing together specialists from around the world to discuss the latest advances in diagnosis, treatment, and clinical research. Held from February 26 to 28, 2026, at the Moscone Center in San Francisco, California (USA), the symposium is a reference point for the presentation of new scientific data, results fr

OncologyESMO®2025
October 18, 2025
3 min read

Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer

Breast cancer is the second most common type of cancer and one of the leading causes of cancer-related death worldwide. HER2 is a tyrosine kinase receptor protein with a growth-promoting function, present on the surface of several tumor types, including breast cancer. HER2 protein overexpression, often due to gene amplification, is associated with more aggressive disease and poorer prognosis. Approximately one in five cases of breast cancer is classified as HER2-posit

Dr. Pedro Barros

Written by Dr. Pedro Barros

About

Master of Health Sciences in Clinical Research — Duke University Doctor of Medicine in Cardiology — Universidade Federal de São Paulo Medical Researcher at the Research Institute of Hospital do Coração and at the Brazilian Clinical Research Institute (BCRI) Director of the Brazilian Society of Internal Medicine and Member of the Guidelines Standardization Council of the Brazilian Society of Cardiology Fellow of the American College of Physicians, the American College of Cardiology, and the European Society of Cardiology Member of the Executive Committee of the Global Heart Attack Treatment Initiative (GHATI) — American College of Cardiology Academic Chief Medical Officer, TribeMD Group